Вот она [Ссылки доступны только зарегистрированным пользователям ]

As mentioned, MMI, PTU, and CM also effectively cross
the placenta, and therefore ATD therapy for maternal hyperthyroidism
also modulates fetal thyroid function. Importantly,
all ATDs tend to be more potent in the fetus than in the mother.
Thus, when the mother is made euthyroid, the fetus is often
overtreated (395). Therefore, in order to avoid a deleterious
fetal impact, the aim of treatment is to maintain maternal TT4/
FT4 values at, or just above the pregnancy-specific upper limit
of normal